Ekso Bionics Holdings, Richmond, California, announced that it effected a one-for-seven reverse split of its common stock at the close of market on May 4. The reverse stock split was approved by the company’s board of directors and is intended to allow the company to meet the minimum share price requirement for listing on the NASDAQ Capital Market. The company said it believes that it currently meets all of the requirements for listing the company’s common stock on the NASDAQ Capital Market other than the minimum trading price requirement. However, there is no assurance that the company’s listing application will be approved.
The temporary ticker symbol, EKSOD, will remain in effect for 20 trading days to signify that the reverse stock split has occurred, after which it will revert back to EKSO. In addition, the company’s common stock will trade under a new Committee on Uniform Security Identification Procedures (CUSIP) number, 282644202, as a result of the reverse split.
